Regional Content Customized for the United Kingdom (UK)

This section contains resources customized for the UK healthcare professional.

Stage III Decision-Support Materials

Updated Stage III Decision Support Tool

The Decision-Support Tool has been updated with information you need to know about outcomes for Stage III melanoma, long-term data for adjuvant therapies, and additional resources, including content specific for caregivers.

Developed in collaboration with the Melanoma UK.

New Stage III Companion Piece

Want to learn how to use the Stage III Decision-Support Tool? Peruse frequently asked questions about Stage III melanoma and learn how to use the support tool to guide your decision making.

Developed in collaboration with the Melanoma UK.

Optimising Care During the COVID-19 Pandemic

In the series of videos below, Emmanouil Nikolousis, FRCP, FRCPath, PhD, MBA, Consultant Haematologist at University Hospitals Birmingham, shares perspectives and tips for optimising care during these challenging times.

Optimising Telemedicine

Use of Extended Dosing Intervals for Immunotherapy

Changes in Infusion Practices

Minimising the Impact on Clinical Trials

Care Step Pathways

This section provides stand-alone Care Step Pathways (CSPs) that have been customized for the UK audience. We wish to thank Emmanouil Nikolousis, FRCP, FRCPath, PhD, MBA, Consultant Haematologist at University Hospitals Birmingham, for thoughtful review of these materials.


List of CSPs

For Immunotherapy (Checkpoint Inhibitors):
Ipilimumab
Nivolumab
Pembrolizumab
Nivolumab/Ipilimumab

For Intralesional Therapy:
Talimogene laherparepvec; T-VEC

Patient Resources

Action Plans

This section contains the customizable action plans for patients with different tumor types that have been customized for the UK audience. We wish to thank Kris Griffin, patient advocate, for his helpful review of these materials.

Talimogene laherparepvec; T-VEC

Pembrolizumab

Nivolumab

Nivolumab/Ipilimumab

Ipilimumab